About This Video
On the latest CSE Issuer Update, we hear from Salim Dhanji, CEO of ME Therapeutics Inc. (CSE: METX).
ME Therapeutics is a Vancouver-based biotechnology company developing next-generation cancer treatments that reprogram a patient’s immune system to fight their own disease. The company’s lead program targets the G-CSF protein—overexpressed in several cancers and a key driver of immune suppression. By blocking G-CSF, ME Therapeutics has shown the ability to trigger strong anti-cancer immune responses in preclinical studies.
Since listing on the CSE 18 months ago, ME Therapeutics has completed toxicology studies to de-risk its lead program, advanced cell line development ahead of a first-in-human clinical trial planned for 2026, and demonstrated proof-of-concept for reprogramming immune cells in vivo. The company also opened a new Vancouver research facility in early 2025 to expand its scientific team and accelerate discovery.
As Salim notes: “We’re really excited about in vivo reprogramming of immune cells—the cost and timelines of drug development have shrunk with this new methodology, and it’s going to change the way patients are treated in the very near future.”
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
Mi Therapeutics is a Vancouver-based biotechnology company and what we do is we develop drugs that reprogram a patient's immune system to fight their own cancer. What what our drugs do is instead of targeting the cancer cells directly, our drugs target the patient's immune system to overcome suppression, which then allows the patient's own immune cells to go in and fight the cancer. This area of research is called
imuninooncology and it's become one of the hottest areas of cancer research over the last 10 to 15 years. One of the challenges with imuninooncology is that even though there are patients who respond well to the current treatments the majority of patients do not respond and so there is a large unmet need for drugs that can overcome suppression in patients who can't be treated with the current drugs. And and
that's what Mi Therapeutics really was founded to do. Our lead drug development program targets a protein called GCSF which is overexpressed in several cancers. And the overexpression of GCSF leads to a large amount of immune suppression. What our data has shown is that if you block GCSF, you can actually get a strong anti-cancer immune response to happen at least in animals. And so our plan is to continue advancement of
our lead drug candidate and move it towards a clinical trial. The other area that we've been really excited about is we've been working on ways to genetically reprogram immune cells in patients in order to make them recognize and kill their own cancer more effectively. And we've been working with a local partner in Vancouver called Nanovations Therapeutics who we believe may have one of the best-in-class solutions for the delivery of nucleic
acidbased drugs to immune cells in the tumor micro environment. And so we're working very closely with them to develop our next generation of drugs which we can use to reprogram immune cells and make them more effective at getting rid of patients cancers. Since MEI Therapeutics was listed on the CSSE about 18 months ago, we've made a lot of lot of exciting progress. Our lead GCSF drug candidate, we were able to carry
out toxicology studies to derisk the program. we also started the cellline development with our partner out in Montreal in advance of our first inhuman clinical study which we're hoping to initiate in 2026. We also did proof of concept studies looking at the delivery of nucleic acids to immune cells in vivo and showing that we were able to reprogram them to treat cancer. In addition to that, you know,
we opened our new labs in January of 2025. we have our brand new research facility. We've been able to hire new scientists. we've also brought on consultants with a lot of background and expertise to help us on the next stages of company development. MI Therapeutics has a lot of exciting things on the go. We we feel like we have a drug discovery and development
program where we're going after targets which will play a key role in immune suppression and we think that they'll have a place in the market going forward in terms of being able to treat multiple types of cancer. We're really excited about this invivo reprogramming of immune cells. the reason being that you know the the cost and the timelines of drug development have shrunk with this new methodology and
we're really excited how that's going to change the way patients are treated in the very near future and we'll be able to provide you know treatments for patients who have no other options. So, the company is ME Therapeutics Holdings Incorporated. We're listed on the CSC. Our ticker is MEX. You can go to our website for more information. mither therapeutics.com.



